NewEdge Advisors’s GT Biopharma GTBP Stock Holding History

NewEdge Advisors’s Portfolio GTBP Stock Details GTBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-3	Closed	–	–	3726
2022 Q4	$0	Buy	+3	New	+$150	﹤0.01%	4130

Other funds holding GTBP

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BFS

Baskin Financial Services Toronto, Ontario, Canada $1.27B AUM 9.68% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NewEdge Advisors's GTBP Position: Q1 2023 in Review

NewEdge Advisors sold out of GT Biopharma (GTBP) in Q1 2023, closing a stake of 3 shares.

NewEdge Advisors first reported a position in GTBP in Q4 2022 and held it in 1 quarter. The position peaked at $0 in Q4 2022. 35 funds tracked by Wall St. Rank hold GTBP as of Q1 2023.

NewEdge Advisors reported no remaining GT Biopharma position as of Q1 2023 after selling out during the quarter.
NewEdge Advisors sold 3 GT Biopharma shares in Q1 2023.
NewEdge Advisors first reported a position in GT Biopharma in Q4 2022 and held it in 1 quarter.
NewEdge Advisors's GT Biopharma position peaked at $0 in Q4 2022.
35 funds tracked by Wall St. Rank held GT Biopharma as of Q1 2023.

Based on NewEdge Advisors's 13F filing for Q1 2023, filed 12 May 2023.